Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03801265
Other study ID # PRO18120275
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date March 19, 2019
Est. completion date May 30, 2020

Study information

Verified date June 2021
Source University of Pittsburgh
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Lumbar Plexus (LP) block is currently used as the standard-of-care regional anesthesia technique to provide postoperative pain management after primary hip replacement surgery at UPMC Shadyside Hospital. However, the LP technique is complex and can be associated with potentially serious side effects, including nerve injury, major bleeding, retroperitoneal hematoma, and intrathecal injection of local anesthetic. In rare instances the LP block can also lead to motor blockade, interfering with early ambulation. There are several case reports of Quadratus Lumborum inter-fascial block (QL3) giving equally adequate pain relief after total hip replacement surgery, and this QL3 block is performed routinely at this institution. The benefits to inter-fascial administration of local anesthetic include the avoidance of theoretical nerve injury, bleeding and intrathecal anesthetic administration associated with the direct interaction between the nerve and the nerve block needle. The purpose of this study is to show that QL3 block is non-inferior to the standard-of-care lumbar plexus block and should be used more regularly in hip replacement surgery. The study will be conducted as a prospective, randomized (1:1), double-blind, non-inferiority, active-comparator trial. The investigators plan to enroll 40 subjects, 20 in each treatment group. This study will prospectively investigate the efficacy of QL3 versus Classic LP block for post-operative pain management in subjects undergoing primary, unilateral hip replacement surgery and prospectively compare QL3 versus Classic LP block in time to mobilization and physical therapy response. Primary outcome measures include pain at rest and with movement at 6, 12 and 24 hours after surgery. Secondary outcomes will be time for first request for pain medication, total pain medications (narcotics and non-narcotic analgesics) given in 24 hours and the time of participant's ability to walk 100 feet as recorded by a physical therapist.


Description:

Eligible patients will be approached for the study by the PI or Sub-I in the pre-operative area on their day of surgery. The anesthesiology investigator will speak with the patient about the study behind a closed drape and the patient will have adequate time to consider the consent and ask questions regarding risk factors associated with each type of block. Once consented, the patient will be randomized by computer generated random number to one of the two treatment groups. Once assigned the treatment allocation, only the clinician administering the block will be unblinded to the randomization outcome. If randomized to the LP block, an anesthesiologist on the Acute Interventional Perioperative Pain Service (AIPPS) will administer the block with this approach: Patient will be positioned in lateral decubitus position with side to be blocked facing upwards. Midline will be identified by palpating the spinous process. Intercristal line will be drawn connecting iliac crests. The point of needle insertion will be 4 cm lateral to the intersection of both lines. The transverse process will first contact with a finder needle. Subsequently an 18 gauge 10 cm insulated needle will be used and advanced until it contacted the transverse process. Needle will then be redirected cephalad or caudad and advanced 1 cm, until the quadriceps femoris twitch is obtained. Local anesthetic will then be injected after confirming a motor response between 0.3-0.5 milli amperes.If randomized to the QL3 block, an anesthesiologist on the Acute Interventional Perioperative Pain Service (AIPPS) will administer the block with this approach:Patient will be placed in a lateral position with the side to be blocked facing up. A low frequency transducer will be used to identify three layers of abdominal musculature, probe will be then moved posteriorly till the transverse abdominus aponeurosis is visualized, the QL muscle is then identified by tracing the aponeurosis posteriorly. The transducer is then moved more posteriorly to visualize the shadow of transverse process and the origin of QL muscle. Psoas muscle is then identified lying anterior to the QL muscle. A 22 gauge 8 cm is inserted in plane posterior to the probe and advanced intramuscularly through the QL to interfacial plane between QL and psoas major and local anesthetic is deposited. For both treatment groups, the local anesthetic used will be 100 mg 0.5% ropivacaine. After surgery, the patient will be followed by the blinded research team for incidence of adverse events, as well as the collection of the primary outcome measures. These include pain at rest and with movement at 6, 12 and 24 hours after surgery, time for first request for pain medication, total pain medications (narcotics and non-narcotic analgesics) given in 24 hours and the time of participant's ability to walk 100 feet as recorded by physical therapist. This information will be captured from the patient's electronic medical record. Minor changes were made to the outcome measures after the original approval of this submission. This was only to clarify the specific measures from the more general descriptions in the original.


Recruitment information / eligibility

Status Completed
Enrollment 46
Est. completion date May 30, 2020
Est. primary completion date May 30, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: 1. Patients 18-90 years old 2. Primary unilateral total hip arthroplasty 3. BMI 20 - 36 4. Male and Female 5. All races Exclusion Criteria: 1. Patient refusal 2. ASA class > or = 4 3. Pregnancy 4. Any condition precluding patient going home with in 24 hours of surgery 5. Non-English speaking or inability to participate in the study 6. Patients with coagulopathy or on therapeutic anticoagulation 7. Chronic Steroid Use 8. Narcotic Addiction

Study Design


Intervention

Procedure:
Lumbar plexus block
Patient will be positioned in lateral decubitus position with side to be blocked facing upwards. Midline will be identified by palpating the spinous process. Intercristal line will be drawn connecting iliac crests. The point of needle insertion will be 4 cm lateral to the intersection of both lines. The transverse process will first contact with a finder needle. Subsequently an 18 gauge 10 cm insulated needle will be used and advanced until it contacted the transverse process. Needle will then be redirected cephalad or caudad and advanced 2 cm, until the quadriceps femoris twitch is obtained. Local anesthetic will then be injected after confirming a motor response between 0.3-0.5 milli amperes.
Quadratus lumborum type 3 block
Patient will be placed in a lateral position with the side to be blocked facing up. A low frequency transducer will be used to identify three layers of abdominal musculature, probe will be then moved posteriorly till the transverse abdominus aponeurosis is visualized, the QL muscle is then identified by tracing the aponeurosis posteriorly. The transducer is then moved more posteriorly to visualize the shadow of transverse process and the origin of QL muscle. Psoas muscle is then identified lying anterior to the QL muscle. A 22 gauge 8 cm is inserted in plane posterior to the probe and advanced intramuscularly through the QL to interfacial plane between QL and psoas major and local anesthetic is deposited.
Drug:
Ropivacaine injection
0.5% ropivacaine 20 ml (100 mg) will be injected for both groups.

Locations

Country Name City State
United States UPMC Presbyterian-Shadyside Hospital Pittsburgh Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Sharad Khetarpal

Country where clinical trial is conducted

United States, 

References & Publications (8)

Adhikary SD, Short AJ, El-Boghdadly K, Abdelmalak MJ, Chin KJ. Transmuscular quadratus lumborum versus lumbar plexus block for total hip arthroplasty: A retrospective propensity score matched cohort study. J Anaesthesiol Clin Pharmacol. 2018 Jul-Sep;34(3):372-378. doi: 10.4103/joacp.JOACP_335_17. — View Citation

Børglum J, Moriggl B, Jensen K, Lønnqvist P, Christensen AF, Sauter A, Bendtsen TF. Ultrasound-guided transmuscular quadratus lumborum blockade. British Journal of Anaesthesia 111:eLetters Supplement, 2013.

Hockett MM, Hembrador S, Lee A. Continuous Quadratus Lumborum Block for Postoperative Pain in Total Hip Arthroplasty: A Case Report. A A Case Rep. 2016 Sep 15;7(6):129-31. doi: 10.1213/XAA.0000000000000363. — View Citation

Ilfeld BM, Ball ST, Gearen PF, Le LT, Mariano ER, Vandenborne K, Duncan PW, Sessler DI, Enneking FK, Shuster JJ, Theriaque DW, Meyer RS. Ambulatory continuous posterior lumbar plexus nerve blocks after hip arthroplasty: a dual-center, randomized, triple-masked, placebo-controlled trial. Anesthesiology. 2008 Sep;109(3):491-501. doi: 10.1097/ALN.0b013e318182a4a3. — View Citation

Ilfeld BM, Duke KB, Donohue MC. The association between lower extremity continuous peripheral nerve blocks and patient falls after knee and hip arthroplasty. Anesth Analg. 2010 Dec;111(6):1552-4. doi: 10.1213/ANE.0b013e3181fb9507. Epub 2010 Oct 1. — View Citation

La Colla L, Ben-David B, Merman R. Quadratus Lumborum Block as an Alternative to Lumbar Plexus Block for Hip Surgery: A Report of 2 Cases. A A Case Rep. 2017 Jan 1;8(1):4-6. doi: 10.1213/XAA.0000000000000406. — View Citation

Weller RS, Gerancher JC, Crews JC, Wade KL. Extensive retroperitoneal hematoma without neurologic deficit in two patients who underwent lumbar plexus block and were later anticoagulated. Anesthesiology. 2003 Feb;98(2):581-5. — View Citation

Winnie AP, Ramamurthy S, Durrani Z, Radonjic R: Plexus blocks for lower extremity surgery: New answers to old problems. Anesth Review 1974; 1:11

Outcome

Type Measure Description Time frame Safety issue
Primary Pain at Rest After Surgery Visual Analog Scale (VAS) score (0-10, 0 means no pain, 10 means the worst pain) of pain at rest. A higher score means worse outcomes. 6 hours after surgery
Primary Pain With Movement After Surgery Visual Analog Scale (VAS) score (0-10, 0 means no pain, 10 means the worst pain) of pain with movement. A higher score means worse outcomes. 6 hours after surgery
Primary Pain at Rest After Surgery Visual Analog Scale (VAS) score (0-10, 0 means no pain, 10 means the worst pain) of pain at rest. A higher score means worse outcomes. 12 hours after surgery
Primary Pain With Movement After Surgery Visual Analog Scale (VAS) score (0-10, 0 means no pain, 10 means the worst pain) of pain with movement. A higher score means worse outcomes. 12 hours after surgery
Primary Pain at Rest After Surgery Visual Analog Scale (VAS) score (0-10, 0 means no pain, 10 means the worst pain) of pain at rest. A higher score means worse outcomes. 24 hours after surgery
Primary Pain With Movement After Surgery Visual Analog Scale (VAS) score (0-10, 0 means no pain, 10 means the worst pain) of pain with movement. A higher score means worse outcomes. 24 hours after surgery
Secondary Pain During Physical Therapy Visual Analog Scale (VAS) score (0-10, 0 means no pain, 10 means the worst pain) of pain with movement. A higher score means worse outcomes. 24 hours after surgery
Secondary Total Opioid Consumption During 24 Hours After Surgery Narcotics will be converted to oral morphine equivalents 24 hours after surgery
Secondary Postoperative Time to Accomplish Walking 100 Feet This measurement is from T0 being out of surgery room time to the point at which the participant was able to walk 100 feet during the first day post-surgery. Values were abstracted from the patient medical records. within 24 hours after surgery
Secondary Block Procedure Duration Duration that the patient underwent the block procedure during surgery in minutes during surgery
Secondary Patients With Postoperative Quadriceps Weakness patients who report having post-surgical quadriceps weakness. 12 hours after surgery
Secondary Total Acetaminophen Consumption During 24 Hours After Surgery Patient electronic medical records were reviewed for total acetaminophen consumption during 24 hours after surgery in milligrams (mg) 24 hours after surgery
Secondary Total Celecoxib Consumption During 24 Hours After Surgery Patient electronic medical records were reviewed for total celecoxib consumption during 24 hours after surgery in milligrams (mg) 24 hours after surgery
Secondary Total Ketorolac Consumption During 24 Hours After Surgery Patient electronic medical records were reviewed for total ketorolac consumption during 24 hours after surgery in milligrams (mg) 24 hours after surgery
Secondary Total Gabapentin Consumption During 24 Hours After Surgery Patient electronic medical records were reviewed for total gabapentin consumption during 24 hours after surgery in milligrams (mg) 24 hours after surgery
Secondary Total Oral Ketamine Consumption During 24 Hours After Surgery Patient electronic medical records were reviewed for total oral ketamine consumption during 24 hours after surgery in milligrams (mg) 24 hours after surgery
Secondary Opioid Consumption During 0-6 Hours After Surgery Narcotics will be converted to oral morphine equivalents 6 hours after surgery
Secondary Opioid Consumption During 6-12 Hours After Surgery Narcotics will be converted to oral morphine equivalents 6-12 hours after surgery
Secondary Opioid Consumption During 12-24 Hours After Surgery Narcotics will be converted to oral morphine equivalents 12-24 hours after surgery
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03326804 - H1 Hip Resurfacing Arthroplasty
Not yet recruiting NCT04257682 - Regional Anesthesia in Total Hip and Knee Arthroplasty Phase 4
Completed NCT02876120 - The STavanger osteoARThritis Study N/A
Terminated NCT02231567 - Neurocognitive Rehabilitation After Hip Replacement N/A
Recruiting NCT02174965 - Wear and Migration in the Corin Mini-Hip/Metafix and ECIMA Polyethylene N/A
Completed NCT01506024 - Minimal Invasive Surgery in Total Hip Arthroplasty Patients; Short- and Long Term Results N/A
Active, not recruiting NCT04070027 - Progressive Resistance Training Versus Total Hip Arthroplasty in Patients With Hip Osteoarthritis N/A
Withdrawn NCT04421196 - Opioid-free Total Hip Arthroplasty N/A
Not yet recruiting NCT05960903 - Patient Satisfaction After Primary THA In Assiut University
Completed NCT04084704 - A Prospective Evaluation of the Cingal Injection for Hip Osteoarthritis N/A
Not yet recruiting NCT04018690 - Project Arthritis Recovering Quality of Life Through Education - Hip N/A
Completed NCT03648060 - Efficacy of a Digital Biofeedback System for Home-based Rehabilitation After Total Joint Replacement N/A
Recruiting NCT05497349 - Use of Leukocyte-Rich PRP or Leukocyte-Free PRP in the Treatment of Hip Osteoarthritis N/A
Active, not recruiting NCT04879732 - RSA - ACTIS Hip Stem N/A
Active, not recruiting NCT05142462 - Post Market Clinical Follow-up of EUROSCUP Fixe Acetabular Cup
Recruiting NCT04665908 - PT-led Triage for Patients With Hip o Knee Osteoarthritis N/A
Completed NCT04648956 - Arabic Version of the ICOAP Questionnaire
Recruiting NCT05465096 - Treatment of Osteoarthritis of the Hip Joint With Intra-articular Injection of Microfractured Autologous Adipose Tissue Containing Mesenchymal Stromal Cells. N/A
Completed NCT02884531 - Patient Education and Basic Body Awareness Therapy in Hip Osteoarthritis: a Randomized Controlled Trial N/A
Completed NCT03031314 - Comparison of Knotless Barbed Suture and Standard Suture in Knee Replacement Patients N/A